Immunic AG | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
Immunic AG

BRIEF

published on 10/29/2024 at 11:35, 23 days 1 hour ago

Immunic participera à des conférences clés tout au long du mois de novembre

Biotechnologie Conférences Investisseurs Essais Cliniques Immunique
PRESS RELEASE

published on 10/29/2024 at 11:30, 23 days 1 hour ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific
BRIEF

published on 10/22/2024 at 12:35, 30 days ago

Immunic Reports Positive Interim Results for Phase 3 ENSURE Program

Biotechnology Vidofludimus Calcium Phase 3 Trials Relapsing Multiple Sclerosis Interim Analysis
BRIEF

published on 10/22/2024 at 12:35, 30 days ago

Immunic annonce des résultats intermédiaires positifs pour la phase 3 du programme ENSURE

Biotechnologie Essais De Phase 3 Vidofludimus Calcique Sclérose En Plaques Récurrente Analyse Intermédiaire
PRESS RELEASE

published on 10/22/2024 at 12:30, 30 days ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 3 ENSURE Program
BRIEF

published on 09/18/2024 at 12:35, 2 months 3 days ago

Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Multiple Sclerosis Immunic Vidofludimus Calcium Neuroprotection ECTRIMS 2024
BRIEF

published on 09/18/2024 at 12:35, 2 months 3 days ago

Immunic dévoile des données prometteuses sur le vidofludimus calcique au congrès ECTRIMS

Sclérose En Plaques Neuroprotection Immunique Vidofludimus Calcique ECTRIMS 2024
PRESS RELEASE

published on 09/18/2024 at 12:30, 2 months 3 days ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark

Multiple Sclerosis Immunic Vidofludimus Calcium Therapeutic Potential ECTRIMS
BRIEF

published on 09/04/2024 at 12:35, 2 months 17 days ago

Immunic recrute son premier patient pour un essai de phase 2 sur le syndrome post-COVID

Essai Clinique Vidofludimus Calcique Syndrome Post-COVID Traitement De La Fatigue Virus D'Epstein-Barr
BRIEF

published on 09/04/2024 at 12:35, 2 months 17 days ago

Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome

Clinical Trial Vidofludimus Calcium Post COVID Syndrome Fatigue Treatment Epstein-Barr Virus

Accesswire

Published on 11/21/2024 at 12:00, 44 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 44 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 14 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 41 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 44 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 9 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 29 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 37 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 44 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 14 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 46 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 36 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 24 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE